429 related articles for article (PubMed ID: 17609904)
1. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
2. Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center.
Estey EH; Hutchinson F
J Clin Oncol; 2011 Jul; 29(20):2743-6. PubMed ID: 21646610
[No Abstract] [Full Text] [Related]
3. Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure.
Yoon HS; Park TS; Jeong KH
Pediatr Blood Cancer; 2011 Dec; 57(6):1085. PubMed ID: 21656902
[No Abstract] [Full Text] [Related]
4. Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
Breccia M; Cicconi L; Minotti C; Latagliata R; Giannì L; Lo-Coco F
Haematologica; 2011 Sep; 96(9):1390-1. PubMed ID: 21659361
[No Abstract] [Full Text] [Related]
5. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
6. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
7. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Sasaki M; Sugimoto K; Isobe Y; Oshimi K
Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
[No Abstract] [Full Text] [Related]
8. Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
Visani G; Piccaluga PP; Martinelli G; Rossi M; Malagola M; Baccarani M
Haematologica; 2003 Apr; 88(4):ELT15. PubMed ID: 12681992
[No Abstract] [Full Text] [Related]
9. Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
Krishna R; Sorour Y; Goepel JR; Kirkbride P; Smith DJ; Ezaydi Y; Dalley CD; Snowden JA
Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):769-71. PubMed ID: 18995171
[No Abstract] [Full Text] [Related]
10. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lo Coco F
Haematologica; 2002 May; 87(5):452-3. PubMed ID: 12010655
[No Abstract] [Full Text] [Related]
12. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
Galimberti S; Papineschi F; Carmignani A; Testi R; Fazzi R; Petrini M
Bone Marrow Transplant; 1999 Aug; 24(3):345-8. PubMed ID: 10455379
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
Park JH; Tallman MS
Oncology (Williston Park); 2011 Jul; 25(8):733-41. PubMed ID: 21874835
[TBL] [Abstract][Full Text] [Related]
15. Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary.
Tallman MS; Manji GA
Blood Cells Mol Dis; 2011 Feb; 46(2):173-4. PubMed ID: 21227722
[No Abstract] [Full Text] [Related]
16. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
17. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Tallman MS
Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
[No Abstract] [Full Text] [Related]
18. Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
Powell BL
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1317-9. PubMed ID: 21929304
[No Abstract] [Full Text] [Related]
19. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
[TBL] [Abstract][Full Text] [Related]
20. Comparing two arsenic trioxide administration methods in APL therapy.
Zhou J; Meng R; Yang BF
Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
[No Abstract] [Full Text] [Related]
[Next] [New Search]
